We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cizzle Biotechnology Holdings Plc | LSE:CIZ | London | Ordinary Share | GB00BNG2VN02 | ORD 0.01P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.375 | 973,569 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.25 | 2.50 | 2.375 | 2.375 | 2.375 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | -912k | -0.0025 | -9.48 | 8.62M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:20:06 | O | 20,000 | 2.40 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 28/9/2023 | 17:29 | ALNC |  EARNINGS: Cizzle Biotechnology loss widens as admin costs mount |
| 28/9/2023 | 06:00 | UKREG | Cizzle Biotechnology Holdings PLC Interim Results |
| 21/9/2023 | 10:14 | ALNC | Vela Technologies and Cizzle Biotechnology rise on Conduit listing |
| 21/9/2023 | 06:00 | UKREG | Cizzle Biotechnology Holdings PLC Update on Put Option with Conduit |
| 19/9/2023 | 16:26 | ALNC | TRADING UPDATES: Tekcapital's portfolio company seals joint venture |
| 19/9/2023 | 06:00 | UKREG | Cizzle Biotechnology Holdings PLC Completion of Evaluation Programme with.. |
| 08/9/2023 | 13:29 | ALNC | Cizzle says meeting to approve sale of AZD1656 interest postponed |
| 08/9/2023 | 06:03 | UKREG | Cizzle Biotechnology Holdings PLC Extension of and update on Put Option.. |
| 15/8/2023 | 09:48 | ALNC | Murphy Canyon to hold meeting on planned buy of interest in AZD1656 |
| 15/8/2023 | 06:00 | UKREG | Cizzle Biotechnology Holdings PLC Update on Put Option with Conduit |
Cizzle Biotechnology (CIZ) Share Charts1 Year Cizzle Biotechnology Chart |
|
1 Month Cizzle Biotechnology Chart |
Intraday Cizzle Biotechnology Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/12/2023 | 17:04 | Cizzle Biotechnology Holdings PLC | 2,111 |
| 02/10/2023 | 07:07 | Cizzle Biotech | 498 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 03/12/2023 08:20 by Cizzle Biotechnology Daily Update Cizzle Biotechnology Holdings Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker CIZ. The last closing price for Cizzle Biotechnology was 2.38p.Cizzle Biotechnology currently has 363,841,773 shares in issue. The market capitalisation of Cizzle Biotechnology is £8,623,050. Cizzle Biotechnology has a price to earnings ratio (PE ratio) of -9.48. This morning CIZ shares opened at 2.38p |
Posted at 02/12/2023 17:04 by oapknob1 So CIZ paid out £255,000 cash for economic interest in AZD1656. Then get paid £200,000 by SGSC so £55,000 paid out and the 5% interest was settled with issuing shares in CIZ to a value of £1,880,000. They executed the put and received £3,250,000 worth NASDAQ shares in CDT at $10 a share. Whats terrible ? (Other than current CDT share price)20 September 2021"SGSC to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street's therapeutic asset AZD1656 of up to GBP5 million, plus potentially further payments from the use of a companion diagnostic.""Under the full commercial contract entered into, in consideration of the potential future royalty stream from the commercialisation of AZD1656 , Cizzle Biotechnology is to pay GBP135,000 to SGSC."22 October 2021"Research and Development agreement worth up to GBP1 million signed for potential autoimmune disease testing and possible additional companion diagnostics.""SGSC will pay Cizzle Biotechnology GBP200,000 upfront on commencement of the project and then further milestone payments totalling up to GBP1 million. "14 February 2022Agreement with Conduit and SGSC to acquire a 5% economic interest for a total consideration of GBP1.88 million, to be settled in new Cizzle ordinary shares at a price of 4.0p per share, a 56.9% premium to the closing mid-market price on 11 February 2022"The Agreement is in addition to the Company's existing interest in AZD 1656 as announced on 20 September 2021"29 September 2022has settled the remaining consideration of GBP880,000 due under the Agreement through the issue of 22,000,000 new ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at 4.0p per share (the "Agreement Shares") to Conduit.19 December 2022"Put Option for Sale of Economic Interest and Royalty Sharing Agreement in AZD1656""Cizzle has agreed to pay Conduit GBP120,000 in cash as the premium for the Option" |
Posted at 02/12/2023 09:44 by secretsqu SE, you're question over on the Vela board...Also you have to ask the question - why did Conduit offer Vela a better deal than Cizzle for their share of Royalty ?CIZ were offered $10/share fixed priceDifferent terms. Vela paid £400k for their put option whereas Ciz paid £120k. |
Posted at 27/11/2023 22:19 by oapknob1 Variation to GBP500,000 Loan FacilityPursuant to its facility agreement with E3 Fund share price (the "Investor") entered into on 20 September 2022 ("Facility") and amended on 21 April 2023, the Company and the Investor are pleased to announce they have agreed to vary the terms of the Facility to enable the Subscription to proceed at a premium to the fixed repayment price of the Facility of 1.8p per share.The Facility has been extended until 8 December 2024 and will be drawable in tranches of not less than GBP100,000 as requested by the Company or the Investor. The first drawdown will be made available to the Company following Shareholder Approval at the Company's next General Meeting to allot a further 23,809,524 new Ordinary Shares. Repayment of the Facility is to be by way of issue and allotment of new Ordinary Shares in the capital of the Company at a new fixed price equal to the Issue Price of 2.1p per share ("Facility Shares"). |
Posted at 16/11/2023 20:07 by secretsqu "This needs to be above 3p to convince the big hitters for SIX "?The price of the share price is immaterial unless you're a day trader.The big hitters (who are they btw) are waiting for the breakout announcement... clinical trial results.LTHs are here for the outcome of the clinical trial, not the daily share price movements.You won't be concerning yourself with any figure in the low double digits, let alone 3p.Dyor |
Posted at 25/9/2023 09:52 by smithie6 ...well......if CIZ exercises it's option & bags £X million then CIZ has a cash pile ...which is a big % of its cap. value - reduces risk for shareholders - deletes any risk of a capital raise by issuing new shares (which often reduces the share price unless there is good news at the same time) - the takeover value of CIZ goes up - gives CIZ more power & respect in any negotiations that it does including with partners & places that CIZ pays to do work (since they all know that CIZ has a wadge of cash so it will be around for at least X years & can pay its bills) & it gives the mkt confidence or a smile about the capabilities of the bod to do profitable deals. This option deal has been very profitable for CIZ, assuming they cash in. |
Posted at 21/9/2023 21:28 by smithie6 Most of his claimed shorts had share prices <3pVery unusual. And many companies with share prices <3p have small/minute capital value & few financial houses offer shorts for such shares & if they do it is usually only for a nominal amount of money, say £250-£500 per position, with perhaps gearing of 3:1 or 4:1. It's peanuts. But if someone is actually doing it & winning, congrats, but be careful....winning short positions can quickly change to be losing positions. For example if a Russian missile explodes in a NATO country next to Ukraine...or Russia invades a Baltic sea country. |
Posted at 21/9/2023 17:12 by smithie6 No one in their right mind would have a short open in this...which is dependent on the price movement tomorrow of a medical company listing/merger on Nasdaq....the price on Nasdaq could do anything At any time tomorrow afternoon in the UK, CIZ could issue an RNS saying that it has exercised it's option in Conduit & sold all its shares & has obtained X million $ which converts to Y million £ & such an RNS could cause the CIZ share price to move to T pence. No one in their right mind would short such a situation. And of course shorting any company with a cap. value of <10 million is usually madness, especially a medical company trying to create product(s) in the cancer sector. If a tiny medical co. announces "success" then the share prices can go nuts in minutes. |
Posted at 22/3/2023 09:22 by oapknob1 Sooner MURF and Conduit conclude the merger and NASDAQ listing the better for underpinning CIZ share price at these levels. |
Posted at 16/3/2023 15:46 by smithie6 RNS"09/09/2021 7:00am UK Regulatory (RNS & others) TIDMCIZ RNS Number : 1857L 9 September 2021 Cizzle Biotechnology Holdings Plc Encouraging progress on collaboration with St George Street Capital St George Street Capital announces results of the Phase II ARCADIA study of AZD1656 in diabetic patients with COVID-19 Cizzle Biotechnology, the UK based diagnostics developer, is pleased to provide an update on its collaboration with St George Street Capital ("SGSC"), the UK-based biomedical charity. As announced on 22 June 2021, Cizzle Biotechnology signed a Memorandum of Understanding ("MoU") with SGSC covering a proposed collaboration between the parties to develop a companion diagnostic platform for which Cizzle Biotechnology will receive fees of up to GBP1 million. Further, under the MoU, SGSC has agreed to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street Capital's therapeutic asset AZD1656 of up to GBP5 million, plus potentially further payments from the use of the companion diagnostic. SGSC has today announced the results of the ARCADIA trial; a phase II, randomised, double-blind, placebo-controlled clinical trial in 153 patients to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The initiation of the ARCADIA trial was the result of an existing collaboration between SGSC and AstraZeneca as part of its Open Innovation Programme and it was funded by international investment through Excalibur Medicines Ltd and an HM Government grant through the UKRI/Innovate UK programme. SGSC reported there are no safety concerns raised regarding the use of AZD1656 in this patient population and they confirmed that there were strong trends in favour of AZD1656 with respect to mortality. The data from the ARCADIA trial supports continued investigation of AZD1656 for the treatment of diabetics with COVID-19 and in light of these encouraging results, St George Street Capital will undertake commercial discussions with potential licencees and/or fundraise for further clinical trials to investigate AZD1656 in a larger study. Following signature of the MoU, Cizzle Biotechnology expects to enter into a full commercial contract in due course. Whilst any royalty payments to Cizzle Biotechnology are contingent on the successful development of AZD1656, today's announcement by SGSC on the positive results from its clinical trial is significant step forward in Cizzle Biotechnology realising the full potential of its royalty rights in AZD1656. Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "We congratulate St George Street Capital on the success of its ARCADIA clinical trial. This further supports our longer-term ambitions to work closely with St George Street Capital and to leverage the technology and know-how of Cizzle Biotechnology to match diagnostic capabilities with therapeutic need. This will increase product opportunities and potential revenue streams for the Company, in addition to our core focus on developing our blood test for the early detection of a majority of the different forms of lung cancer." Commenting, Professor John Martin of UCL, Chairman of SGSC, said: "The completion of ARCADIA marks a significant milestone in the history of the charity St George Street Capital. We have demonstrated our ability to rapidly deliver a clinical trial in an area of unmet clinical need, thus fulfilling our mission to accelerate the development of new treatments for people who need them. The promising results from this trial indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for COVID-19 - independent of viral mutations - initiating a new wave of therapies for clinicians in meeting this global challenge." Enquiries: Cizzle Biotechnology Holdings Via IFC Advisory plc Allan Syms (Executive Chairman) ......." |
Posted at 16/3/2023 15:22 by smithie6 there is a 3rd RNS about CIZ & deals with Conduit/SGSA14th Feb. 2022 Cizzle Biotechnology Holdings PLC 14 February 2022 This announcement contains inside information for the purposes of article 7 of EU Regulation 596/2014 which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018 ("UK MAR") . Upon the publication of this announcement this inside information is now considered to be within the public domain. 14 February 2022 Cizzle Biotechnology Holdings Plc ("Cizzle Biotechnology", "Cizzle" or the "Company") Acquisition of Royalty Deal in Inflammatory Pulmonary and Cardiovascular Diseases Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has entered into a definitive agreement (the "Agreement") with Conduit Pharmaceuticals Limited ("Conduit") and St George Street Capital Limited ("SGSC") to acquire a 5% economic interest in the commercialisation of the AZD 1656 asset or other such assets being developed by Conduit or SGSC to treat inflammatory pulmonary and cardiovascular disease (the "Economic Interest"). Highlights -- Agreement with Conduit and SGSC to acquire a 5% economic interest for a total consideration of GBP1.88 million, to be settled in new Cizzle ordinary shares at a price of 4.0p per share, a 56.9% premium to the closing mid-market price on 11 February 2022 -- The Agreement is in addition to the Company's existing interest in AZD 1656 as announced on 20 September 2021 -- SGSC recently reported the successful completion of the AZD 1656 ARCADIA clinical trial in Covid-19 and SGSC and Conduit are in discussions with multiple pharmaceutical companies about licensing opportunities for AZD 1656 for Covid-19 and potentially for further indications -- The Agreement supports the Company's ambitions to expand its target customer base into the pharmaceutical industry and is in line with its strategy of building a portfolio of early cancer detection tests, companion diagnostics and royalty bearing stakes in significant drug assets Allan Syms, Executive Chairman of Cizzle Biotechnology, said "The agreement announced today represents an important extension to our close relationship with SGSC and Conduit. On 20 September 2021 we announced we had acquired a stake in SGSC's AZD 1656 asset, providing the opportunity for the Company to receive royalty payments of up to GBP5 million and shortly after SGSC contracted the Company to develop an associated companion diagnostic test for which we will receive fees of up to GBP1 million. "We are now pleased to have the opportunity to increase our stake by an additional 5% in AZD 1656, but significantly the Economic Interest will be uncapped. This new Agreement supports the Company's ambitions to expand its target customer base in the pharmaceutical industry and through a strategy of building a portfolio of early cancer detection tests, companion diagnostics and royalty bearing stakes in significant drug assets significantly increase shareholder value." Background SGSC is a UK-based medical-charity led by a group of highly decorated academics and ex-pharma executives formed to deliver much needed treatments to patients. SGSC's strategy is to take clinical-ready assets from pharmaceutical companies and to progress them through Phase II medical trials, before licensing them on for Phase III trials and commercialisation in order to create a return for investors and the charity alike. SGSC recently reported the successful completion of the AZD 1656 ARCADIA clinical trial in Covid-19 and SGSC and Conduit are in discussion with multiple pharmaceutical companies about licensing opportunities for AZD 1656 in both Covid-19 and potentially in further indications. Conduit is the exclusive funding partner to the Charity. The ARCADIA trial data, that treated inflammatory pulmonary and cardiovascular disease caused by Covid-19, showed a strong trend towards reduced mortality in patients receiving AZD 1656. The strong trend to improved mortality for patients on AZD 1656 was observed on top of patients receiving other medication as part of standard of care. AZD 1656 was also shown to be well-tolerated in this patient population with no serious adverse reactions (SARs) occurring. Overall, no safety concerns were identified regarding the use of AZD 1656 in this patient population. Furthermore, SGSC has shown there was a significant increase in the migration of the Regulatory T Cells ("Tregs") from the patients who had taken the drug compared to the Tregs from the patients who had not. Tregs are a specialised subpopulation of T cells that act to suppress immune response and combat damaging cells, potentially reducing serious cardiovascular and lung diseases which are causative in the development of lung cancer, which Cizzle is developing its diagnostic test to identify. Under the Agreement Cizzle Biotechnology will receive 5% of all such sums received by SGS pursuant to any AstraZeneca ("AZ") commercialisation or sub-license commercialisation of the AZ asset in inflammatory pulmonary and cardiovascular diseases, after the deduction of certain sums. Consideration for the Agreement Under the terms of the Agreement, Cizzle will pay consideration of GBP1.88 million to SGS for the Economic Interest. Of the consideration payable, GBP1.0 million (the "Initial Consideration") will be satisfied by the issue of 25,000,000 new ordinary shares in the Company (the "Consideration Shares"), at a price of 4.0 pence per Consideration Share, being a premium of 56.9 per cent. to the Company's closing mid-market price of 2.55 pence on 11 February 2022. The remaining consideration of GBP880,000 will be payable in new ordinary shares in the Company issued at 4.0 pence per share, on the sooner of receiving shareholder approval to issue the shares or the first anniversary of completion. Total Voting Rights On completion of payment of the Initial Consideration, Conduit will hold 25,000,000 ordinary shares in Cizzle representing 8.98 per cent. of the issued share capital of the Company, as enlarged by the issue of the Consideration Shares. The Company has applied for admission of the 25,000,000 Initial Consideration new Ordinary Shares to trading on the Standard Segment of the Official List and the Main Market of the London Stock Exchange ("Admission"). It is expected that Admission will become effective on or around 17 February 2022. The Company's issued ordinary share capital on Admission will consist of 278,447,788 ordinary shares of 0.1 pence each, all with voting rights. The Company holds no ordinary shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Enquiries: Cizzle Biotechnology Holdings Via IFC Advisory plc Allan Syms (Executive Chairman) Allenby Capital Limited +44(0) 20 33285656 John Depasquale Alex Brearley Novum Securities Limited +44(0) 20 7399 9400 Colin Rowbury Jon Bellis IFC Advisory Limited +44(0) 20 3934 6630 Tim Metcalfe cizzle@investor-focu Florence Chandler Notes to Editors: About Cizzle Biotechnology...... END |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
